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(57) ABSTRACT
The present disclosure describes compositions operable for
releasing nitric oxide under photochemical conditions. The
compositions include a titanium dioxide nanomaterial and a
nitric oxide-releasing compound deposited on the titanium
dioxide nanomaterialthat is operable to release nitric oxide
under photochemical conditions. Titanium dioxide nanoma-
terials include, for example, titantum dioxide nanotubes. To
facilitate the photochemical release of nitric oxide, some
embodiments ofthe compositions further include a semicon-
ductor that is deposited on the titantum dioxide nanotubes.
Both the semiconductor and the nitric oxide-releasing com-
pound maybe deposited on the interior surface, exterior sur-
face, or both of the titantum dioxide nanotubes. A polymer
maywrapthe titanium dioxide nanotubesto protectthe nitric
oxide-releasing compounds from moisture. Also disclosed
herein are methods for producing such compositions and
medical devices obtained therefrom.
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TITANIUM DIOXIDE NANOTUBES FOR
PRODUCTION AND DELIVERY OF NITRIC
OXIDE AND METHODS FOR PRODUCTION
THEREOF
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application claimspriority to U.S. provisional patent
application 61/164,769,filed Mar. 30, 2009, which is incor- 10
porated by reference herein in its entirety.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH
Notapplicable.
BACKGROUND
Nitric oxide (NO) is an endogenous mediator of various
physiological functionsin the gastrointestinal, genitourinary,
cardiovascular, respiratory, andnervous systems. Nitric oxide
has long been established as a signaling molecule that pro-
motesrelaxation ofsmooth muscle cells. More recently, it has
been established or implicated that NO can mediate other
biological processes and diseases including, for example,
wound healing, inflammation, plant disease resistance,
sexual dysfunction, social dysfunction, cancer, coronary
heart disease, restenosis, hypertension and angiogensis.
There are also implicationsofthe role ofNO in organ perse-
veration during transplantation and procurement. The impli-
cation ofNO in so manybiological processes and diseases has
stimulated interest in its exogenousdelivery. However, NO is
a diatomicfree radical, and its exogenousdelivery as a gas to
biological systems has proved impractical due to its high
reactivity.
A numberof systems have been proposedandtested for in
situ generation and delivery ofNO. Such NO-releasing com-
pounds include chemical compoundssuch as, for example,
diazeniumdiolates, S-nitrosothiols, metal nitrosyl com-
plexes, NO-releasing gold nanoparticles, NO-releasing poly-
ethyleneimine (PEI) fibers and NO-releasing zeolites. For
some NO-releasing compounds, the rate ofNO release can be
varied somewhatthrough temperature, pH or enzymatic con-
trol, although most NO-releasing compoundsare non-spe-
cific and release NO spontaneously. Poor solubility and gen-
eration ofpotentially toxic byproducts havefurtherstalled the
use of NO-releasing compounds for exogenous delivery of
NO.
In view of the foregoing, compositions and methodspro-
viding for controlled or sustained release ofNO would be of
substantial benefit in the art. Desirably, such systems would
promote controlled or sustained release ofNO to exploit the
beneficial properties ofNO in biological systems, while at the
same time minimizing the toxicity or biological incompat-
ibility of present NO-releasing materials.
SUMMARY
In various embodiments, the present disclosure describes
compositions operable for release of nitric oxide under pho-
tochemical conditions. The compositions include a titanium
dioxide nanomaterial and a nitric oxide-releasing compound
deposited on the titanium dioxide nanomaterial. The nitric
oxide-releasing compoundis operableto release nitric oxide
under photochemical conditions.
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In other various embodiments, compositions operable for
photochemical release of nitric oxide include titanium diox-
ide nanotubes, a nitric oxide-releasing compound deposited
on the titanium dioxide nanotubes, a semiconducting quan-
tum dot material deposited on the titanium dioxide nanotubes,
and a polymer wrapping the titanium dioxide nanotubes. The
nitric oxide-releasing compoundis operableto release nitric
oxide under photochemical conditions.
In other various embodiments, methods described herein
include: providing titantum dioxide nanotubes, depositing a
nitric oxide-releasing compound on the titanium dioxide
nanotubes and depositing a semiconducting quantum dot
material on the titantum dioxide nanotubes. Thenitric oxide-
releasing compoundis operable to release nitric oxide under
photochemical conditions. At least a portion of the nitric
oxide-releasing compoundandat least a portion of the semi-
conducting quantum dot material are deposited on the exte-
rior surfaceofthe titanium dioxide nanotubes.
In still other various embodiments, methods described
herein include: providing titanium dioxide nanotubes, wrap-
ping the titanium dioxide nanotubes with a cationic surfac-
tant, depositing a nitric oxide-releasing compound on the
titanium dioxide nanotubes and depositing a semiconducting
quantum dot materialon thetitanium dioxide nanotubes. The
nitric oxide-releasing compoundis operableto release nitric
oxide under photochemical conditions. The nitric oxide-re-
leasing compound and the semiconducting quantum dot
material are deposited on the interior surface of the titanium
dioxide nanotubes.
The foregoing has outlined rather broadly the features of
the present disclosure in order that the detailed description
that follows may be better understood. Additional features
and advantagesofthe disclosure will be described hereinaf-
ter, which form the subject of the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
For a more complete understanding of the present disclo-
sure, and the advantagesthereof, reference is now madeto the
following descriptions to be taken in conjunction with the
accompanying drawings describing specific embodiments of
the disclosure, wherein:
FIG. 1 showsanillustrative process through which PbS
quantum dots may be deposited on titanium dioxide nano-
tubes;
FIGS. 2A and 2B show illustrative TEM images of PbS
quantum dots deposited on the interior surface of titanium
dioxide nanotubes;
FIG. 3 shows an illustrative TEM image showing PbS
nanorods within the interior of titanium dioxide nanotubes;
FIG. 4 shows a schematic of an illustrative synthesis of
diazeniumdiolate-modified titanium dioxide nanotubes;
FIG. 5 showsillustrative comparative FTIR spectra ofdia-
zeniumdiolate-modified titanium dioxide nanotubes before
and after exposureto ultraviolet radiation;
FIG. 6 shows a schematic of an illustrative synthesis of
S-nitrosothiol-modifiedtitantum dioxide nanotubes contain-
ing PbS quantum dots;
FIG. 7 showsa plot ofnear-infrared photochemical release
ofNO versustimefor 5-nitrosothiol-modified titanium diox-
ide nanotubes both before andafter purification by filtration;
FIGS. 8A and 8B show illustrative TEM imagesoftita-
nium dioxide nanotubes wrapped with poly-L-arginine;
FIG. 9 showsan illustrative TEM image of Au nanopar-
ticles deposited on titanium dioxide nanotubes; and
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FIG. 10 showsanillustrative confocal microscopy image
ofAu nanoparticles deposited on titanium dioxide nanotubes
after wrapping in poly-L-arginine.
DETAILED DESCRIPTION
In the following description, certain details are set forth
such as specific quantities, sizes, etc. so as to provide a thor-
ough understanding of the present embodiments disclosed
herein. However, it will be evidentto those ofordinary skillin
the art that the present disclosure may be practiced without
such specific details. In many cases, details concerning such
considerations and the like have been omitted inasmuch as
such details are not necessary to obtain a complete under-
standing of the present disclosure and are within the skills of
persons of ordinary skill in the relevantart.
Referring to the drawings in general, it will be understood
that the illustrations are for the purpose ofdescribing particu-
lar embodiments of the disclosure andare not intended to be
limiting thereto. Drawings are not necessarily to scale.
While most ofthe terms used herein will be recognizable to
those of ordinary skill in the art, it should be understood,
however, that when not explicitly defined, terms should be
interpreted as adopting a meaning presently accepted by
those of ordinary skill in theart. In cases where the construc-
tion of a term would render it meaningless or essentially
meaningless, the definition should be taken from Webster’s
Dictionary, 3rd Edition, 2009. Definitions and/or interpreta-
tions should not be incorporated from other patent applica-
tions, patents, or publications, related or not, unless specifi-
cally stated in this specification or if the incorporation is
necessary for maintaining validity.
As used herein, the term “nitric oxide-releasing com-
pound”refers to, for example, a compoundthatreleasesnitric
oxide through a chemical reaction upon exposure to specified
conditions.
Asusedherein, the term “quantum dot material”refers to,
for example, a semiconducting material whose excitons are
confinedin all three spatial dimensions. In such quantum dot
materials, the conduction characteristics are directly related
to the size and shapeofthe individualparticles. Typically, the
smaller the particle size, the larger the semiconducting band
gap.
As used herein, the term “medical device” refers to, for
example, any device used either internally or externally for
treating, mediating, curing or alleviating a condition in a
patient or any device used as part of a medical procedure.
Mammalian cells synthesize NO using a two-step enzy-
matic process that oxidizes L-arginine to N-omega-hydroxy-
L-arginine, which is subsequently converted into L-citrulline
and anunchargedNO free radical. Three different nitric oxide
synthase enzymes regulate NO production. Neuronalnitric
oxide synthase (NOS1 or nNOS)is formed within neuronal
tissue and plays a role in neurotransmission. Endothelial
nitric oxide synthase (NOS3 or eNOS)is secreted by endot-
helial cells and induces vasodilatation. Inducible nitric oxide
synthase (NOS2 or iNOS)is principally found in macroph-
ages, hepatocytes and chondrocytes and is associated with
immunecytotoxicity. Neuronal NOS and eNOSare constitu-
tive enzymes that regulate the rapid, short-term release of
small amounts ofNO.In these minute amounts NO activates
guanylate cyclase, which elevates cyclic guanosine mono-
phosphate (cGMP) concentrations, which in turn increase
intracellular Ca** levels. Increased intracellular Ca** levels
result in smooth muscle relaxation and vasodilation effects.
Inducible NOS is responsible for the sustained release of
larger amounts ofNO andis activated by extracellular factors
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including endotoxins and cytokines. These higher NOlevels
play a role in cellular immunity.
Nitric oxide’s therapeutic potential has been studied in a
numberofdiverse clinical indications including, for example,
cancer, coronary artery heart disease, restenosis, hyperten-
sion, angiogenesis, sexual dysfunction and social dysfunc-
tion. Moreover, recent studies have demonstrated that NO
also possesses considerable in vivo and ex vivo antimicrobial
activity, suggesting a possible role in treating infectious dis-
eases and fungal infections. The role ofNO in woundhealing
and general inflammation has also been studied.
Another postulated clinical role of NO is in the field of
organ transplantation, particularly heart transplantation. One
of the majorfactors in realizing a successful heart transplan-
tation is adequate organ preservation during the procurement,
storage, and implantation stages of a transplant. Currently,
organ preservation is based on a single flush induction of
cardioplegia and hypothermic storage in a solution. While
this methodis effective, time is still the major factor in heal-
ing, becausethe heart can only tolerate 4-5 hours ofischemia.
Prolonged periods of ischemia lead to increased acute and
chronic organ failure due to vasoconstriction and endothe-
lium damageofthe arteries upon a decrease in NO produc-
tion.
Attempts to mimic the natural release ofNO produced by
NOSenzymeshaveyet to be successful. Embodiments ofthe
present disclosure seek to provide compositions permitting
the controlled or sustained release ofNO,either in vivo or ex
vivo. Controlled or sustained release ofNO is accomplished
by utilizing nitric oxide-releasing compoundsthat do not
release NO until an activation event occurs to stimulate NO
release. Nitric oxide release may occur, for example, through
photochemical activation. Such compositions may be sub-
stantially non-toxic to biological systems and/or successfully
mimic the natural enzymatic release of NO. In view of the
established role ofNO in so manybiological processes, such
compositions would undoubtedly demonstrate substantial
utility in the art. Medical and therapeutic devices that contain
such compositions are also contemplated herein.
To mitigate the potential toxicity of some nitric oxide-
releasing compounds, the nitric oxide-releasing compounds
may be deposited on a surface. Surfaces may include metal
oxide surfaces in some embodiments. In some embodiments,
the metal oxide surface mayitself be photoactive to assist in
the photochemical activation of the nitric oxide-releasing
compounds within the compositions. For example, in some
embodiments, the metal oxide surface may betitanium diox-
ide (Ti0,), which is a well-studied material for photocataly-
sis. The titantum dioxide may take the form of a nanoscale
material such as, for example, nanofibers, nanorods or nano-
tubes in order to provide a high surface to volumeratio ben-
eficial for photocatalysis.
In various embodiments, the present disclosure describes
compositions operable for release of nitric oxide under pho-
tochemical conditions. The compositions include a titanium
dioxide nanomaterial and a nitric oxide-releasing compound
deposited on the titanium dioxide nanomaterial. The nitric
oxide-releasing compoundis operableto release nitric oxide
under photochemical conditions. In some embodiments, the
titanium dioxide nanomaterialis titanium dioxide nanotubes.
Nitric oxide-releasing compounds that produce nitric
oxide through a chemical reaction may be considerednitric
oxide prodrugs. Nitric oxide-releasing compounds may
include, for example, organic N-nitro and N-nitroso com-
pounds (for example, diazeniumdiolates), organic O-nitro
and O-nitroso compounds (for example, glyceryl trinitrate
and amy]nitrite), organic C-nitro and C-nitroso compounds
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(for example, nitrolipids, nitronic acids, nitroalkanes, diazet-
ine dioxides and furoxans), S-nitrosophenols, S-nitrosothi-
ols, N-hydroxyurea and derivatives, N-hydroxyguanidine
and derivatives, and nitroprusside ion and other metal nitrosyl
complexes. Among these nitric oxide-releasing compounds,
diazeniumdiolates, S-nitrosothiols and metal nitrosyl com-
plexes are amongthe most studied for photochemical activa-
tion to affect NO release. Although the embodiments and
examples referenced hereinafter have been centered on pho-
tochemically-active diazeniumdiolates, S-nitrosothiols and
metal nitrosyl complexes, one of ordinary skill in theart will
recognize that any nitric oxide-releasing compoundthat is
photochemically active may be used to operate within the
spirit and scope ofthe present disclosure.
The general structural formula of diazeniumdiolates is
exemplified by structure I below, where R and R' are inde-
pendently H or any alkyl, alkenyl, alkynyl, aryl, aralkyl,
alkaryl group or substituted derivative thereof. Charge bal-
ance is generally affected by a monovalentcation such as, for
example, a Na* cation. Diazeniumdiolates are typically
formed by exposing an amineto nitric oxide gas.
oO 0\ _+/
N=
\NRR’
Thestructure of S-nitrosothiols is exemplified by structure
II below.R is any alkyl, alkenyl, alkynyl,ary], aralkyl, alkaryl
group or substituted derivative thereof. Like diazeniumdi-
olates, S-nitrosothiols are typically formed by exposing a
thiol to nitric oxide gas.
Ss
Rm no
Metal nitrosyl complexes typically include at least one to
about 6 nitrosyl ligands coordinated to a metal center. The
metal center may include, for example, transition metals,
lanthanide metals and actinide metals. In some embodiments
of the present disclosure, the metal nitrosyl complex is a
ruthenium nitrosyl complex.
Depending on the band gap, photochemical conditions for
stimulating nitric oxide release from the compositions
described herein may involve irradiating the nitric oxide-
releasing compoundswith a light source such as, for example,
visible light, ultraviolet light, near infrared light, infrared
light and various combinations thereof. In various embodi-
ments, inclusion ofa semiconductor material, such as a quan-
tum dot material, as part of the compositions may lower the
band gap into a lower energy portion of the electromagnetic
spectrum. Particularly for biological applications, it may be
advantageous adjust the band gap into the near-infrared
region of the electromagnetic spectrum (~700 nm-1400 nm)
for stimulatingNO release. Various tissue chloroplasmain the
human body block light penetration except for a narrow
region of about 700 nm to about 1100 nm in thenearinfrared
region of the electromagnetic spectrum. By selectively
adjusting the band gap through inclusion of a semiconductor
material in the compositions of the present disclosure, the
compositions may be designed for in vivo photochemical
release ofNO using a wavelengthoflightthat is not absorbed
by the body.
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In some embodiments, photochemical activation of the
nitric oxide-releasing compound maynot require accessing a
lower energy region of the electromagnetic spectrum, and
photochemical conditions for activating the nitric oxide-re-
leasing compound mayinvolvethe use of an ultraviolet light
source. In such embodiments, non-limiting nitric oxide-re-
leasing compounds may include, for example, diazeniumdi-
olates, S-nitrosothiols and metal nitrosyl complexes.
In some embodiments, compositionsofthe present disclo-
sure further include a semiconductor material deposited on
the titanium dioxide nanotubes. In some embodiments, the
semiconductor materialis PbS. In general, the semiconductor
material may include nanoparticles such as, for example,
PbS, PbSe, CuS, Cu,S, FeS,, CdS, CdSe, CdTe, ZnS, Ag,S,
CulnS,, Rh,S, and RuS,. Such nanoparticles and others may
be quantum dot materials in some embodiments. In some
embodiments, the quantum dot material may be usedto nar-
row the bandgap for absorption ofelectromagneticradiation,
thereby facilitating the photochemicalactivation ofthe nitric
oxide-releasing compoundsin the present compositions. Fur-
ther, by narrowing the band gap, the absorption of electro-
magnetic radiation may be changed into a less energetic and
more generally usable region of the electromagnetic spec-
trum, particularly for in vivo applications.
Lead sulfide (PbS) is a semiconductor material that may
have particular utility in the compositions of the present dis-
closure. This semiconductor material has a small band gap of
about 0.41 eV anda large exciton Bohrradius ofabout 20 nm.
PbS quantum dot materials may further improve upon these
properties due to multiple exciton generation and efficient
spatial separation ofphotogenerated charge, thereby prevent-
ing electron-hole recombination.Further, the band gap ofPbS
quantum dots may be adjusted by varying the size of the
quantum dot materials. For example, for PbS quantum dots
having diameters between about 2 nm and about 9 nm, the
band gap maybetunedin the range of 0.83 eV to 2.34 eV.
Titanium dioxide nanotubes generally have outer diam-
eters ranging from about 10 nm to about 20 nm and inner
diameters ranging from about 5 nm to about 10 nm. Lengths
of the titanium dioxide nanotubes maybe up to about 1 pm.
Both the interior and exterior surfaces ofthe titanium dioxide
nanotubes may be modified with nitric oxide-releasing com-
pounds and semiconductor materials, as described hereinaf-
ter.
In some embodiments, at least a portion of the semicon-
ductor material is deposited on the exterior surface of the
titanium dioxide nanotubes. In some or other embodiments,
at least a portion of the nitric oxide-releasing compoundis
deposited on the exterior surface of the titanium dioxide
nanotubes. In some embodiments, both the interior surface
and exterior surface ofthe titanium dioxide nanotubes contain
the semiconductor material In some or other embodiments,
both the interior surface and exterior surface of the titantum
dioxide nanotubes contain the nitric oxide-releasing com-
pound. In some embodiments, the semiconductor material is
deposited on theinterior surface ofthe titanium dioxide nano-
tubes. In some or other embodiments,the nitric oxide-releas-
ing compound is deposited on the interior surface of the
titanium dioxide nanotubes. Deposition ofthe semiconductor
material and the nitric oxide-releasing compound may be
conducted independently of one another, such that one com-
ponent is deposited on the exterior surface of the titanium
dioxide nanotubes and one component is deposited on the
interior surface of the titanium dioxide nanotubes.
In some embodiments, at least one of the nitric oxide-
releasing compound and the semiconductor material are
covalently boundto the titantum dioxide nanotubes. In some
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or other embodiments, the nitric oxide-releasing compound is
covalently boundto the titantum dioxide nanotubes. In some
or other embodiments, the semiconductor material is
covalently boundto the titantum dioxide nanotubes. In some
embodiments, the nitric oxide-releasing compound is
adsorbed to the titantum dioxide nanotubes. In some embodi-
ments, the semiconductor material is adsorbedto thetitanium
dioxide nanotubes.In an embodiment, adsorptionofthenitric
oxide-releasing compound or the semiconductor material
takes place through a carboxyl group adsorbed onthetita-
nium dioxide nanotube surface.
In some embodiments, compositionsofthe present disclo-
sure further include a polymer wrappingthe titanium dioxide
nanotubes. In some embodiments, the polymer is a water-
soluble polymer. Water-soluble polymers include, for
example, poly-L-arginine, poly(vinyl pyrrolidone), poly(eth-
ylene oxide), poly(acrylic acid), and poly(vinyl alcohol).
However, one of ordinary skill in the art will recognize that
other water-soluble polymers are known and may be used
equivalently within the spirit and scopeofthe present disclo-
sure. Such water-soluble polymers may make the present
compositions water-soluble andfacilitate the transport of the
compositions across cell membranes. Further, the polymer
mayprotect the nitric oxide-releasing compoundsofthe com-
positions from moisture, thereby leaving them in an unacti-
vated form for photochemical release of NO, rather than
producing indiscriminate NO release mediated by water.
In some embodimentsofthe present disclosure, composi-
tions operable for photochemical release of nitric oxide
include titanium dioxide nanotubes, a nitric oxide-releasing
compound deposited on the titanium dioxide nanotubes, a
semiconducting quantum dot material deposited on the tita-
nium dioxide nanotubes, and a polymer wrapping thetita-
nium dioxide nanotubes. The nitric oxide-releasing com-
poundis operable to releasenitric oxide under photochemical
conditions. In some embodiments, the polymer is a water-
soluble polymersuch as, for example, poly-L-arginine. In an
embodiment, the polymerprotects the nitric oxide-releasing
compound from moisture.
In some embodiments of the compositions, at least a por-
tion ofthe semiconducting quantum dot material is deposited
on the exterior surface of the titanium dioxide nanotubes. In
some or other embodiments, at least a portion of the nitric
oxide-releasing compoundis deposited on the exterior sur-
face of the titanium dioxide nanotubes. In some embodi-
ments, both the interior surface and exterior surface of the
titanium dioxide nanotubes contain the semiconducting
quantum dot material. In some or other embodiments, both
the interior surface and exterior surface ofthe titanium diox-
ide nanotubes contain the nitric oxide-releasing compound.
In some embodiments, the semiconducting quantum dot
material is deposited on the interior surface of the titanium
dioxide nanotubes. In some or other embodiments, the nitric
oxide-releasing compoundis deposited on the interior surface
of the titanium dioxide nanotubes. In some embodiments,at
least one of the nitric oxide-releasing compound and the
semiconducting quantum dot material are covalently bound
to the titantum dioxide nanotubes.
In some embodiments, compositionsofthe present disclo-
sure further include a tissue-targeting moiety deposited on the
exterior surface of the titanium dioxide nanotubes. In some
embodiments,the tissue-targeting moiety may be covalently
bondedto the exterior surface of the titanium dioxide nano-
tubes. Illustrative tissue-targeting moieties include, for
example, antibodies, peptides, DNA, RNAandthelike.
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In other various embodiments, the present disclosure
describes methods for producing compositions operable for
releasing nitric oxide under photochemical conditions.
In some embodiments, the methods described herein
include: providing titantum dioxide nanotubes, depositing a
nitric oxide-releasing compound on the titanium dioxide
nanotubes and depositing a semiconducting quantum dot
material on the titantum dioxide nanotubes. Thenitric oxide-
releasing compoundis operable to release nitric oxide under
photochemical conditions. At least a portion of the nitric
oxide-releasing compoundandat least a portion of the semi-
conducting quantum dot material are deposited on the exte-
rior surfaceofthe titanium dioxide nanotubes.
In other embodiments, the methods described herein
include: providing titanium dioxide nanotubes, wrapping the
titanium dioxide nanotubeswith a cationic surfactant, depos-
iting a nitric oxide-releasing compoundonthe titanium diox-
ide nanotubes and depositing a semiconducting quantum dot
material on the titantum dioxide nanotubes. Thenitric oxide-
releasing compoundis operable to release nitric oxide under
photochemical conditions. The nitric oxide-releasing com-
pound and the semiconducting quantum dot material are
deposited on theinterior surface ofthe titanium dioxide nano-
tubes.
In still other embodiments, the methods described herein
include: providing titanium dioxide nanotubes, wrapping the
titanium dioxide nanotubeswith a cationic surfactant, depos-
iting a nitric oxide-releasing compoundonthe titanium diox-
ide nanotubes and depositing a semiconducting quantum dot
material on the titantum dioxide nanotubes. Thenitric oxide-
releasing compoundis operable to release nitric oxide under
photochemical conditions. At least the semiconducting quan-
tum dot material is deposited on the interior surface of the
titantum dioxide nanotubes.
In some embodiments of the methods, at least one of the
nitric oxide-releasing compound and the semiconducting
quantum dot material are covalently boundto the titanium
dioxide nanotubes. In some embodiments, the methods fur-
ther include wrappingthe titanium dioxide nanotubes with a
polymersuch as, for example, a water-soluble polymer.
In various embodiments, the nitric oxide-releasing com-
pounds and the semiconducting quantum dot materials may
be selectively deposited on only the interior surface or the
exterior surfaceofthe titanium dioxide nanotubes.In various
embodiments, the methods of the present disclosure further
include wrappingthe exterior surface of the titantum dioxide
nanotubes with a cationic surfactant, followed by deposition
of the nitric oxide-releasing compoundsand/or the semicon-
ducting quantum dot materials on the interior surface of the
titantum dioxide nanotubes. Whenthe exterior surface ofthe
titanium dioxide nanotubesis blocked with a cationic surfac-
tant, deposition takes place on the interior surface of the
titantum dioxide nanotubes. Whenthe exterior surface ofthe
titantum dioxide nanotubes is not blocked with a cationic
surfactant, deposition may take place either on the exterior
surface or a combinationofthe interior surface and the exte-
rior surface.In light ofthe present disclosure, one ofordinary
skill in the art will recognize that any of the various embodi-
ments described herein having aparticular location for either
of the nitric oxide-releasing compoundsand/or the semicon-
ducting quantum dot materials may be conducted equiva-
lently through routine experimental modification to locate
these moieties at a different location on either the interior
surface or the exterior surface of the titanium dioxide nano-
tubes.
Compositions of the present disclosure may be included
with medical devices. In some embodiments, the composi-
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tions maycoat the surface ofthe medical device. The medical
devices of the present disclosure may be manufactured from
a material such as, for example, metal, glass, ceramic, fabrics
and polymers upon which the compositions described herein
may be deposited.
Medical devices of the present disclosure include stents,
vascular grafts, pacemaker leads, heart valves, electrodes,
sensors, trocars, guide wires, catheters, ocular lenses, sling
materials, sutures, wound dressings and bandages, blood col-
lection bags and storage tubes, tubing for bloodtransfusions
and hemodialysis. In some embodiments, the medical devices
are used internally. Medical devices ofthe present disclosure
maybe usedto treat, mediate or prevent a variety of diseases
in which nitric oxide is implicated as having a functionalrole.
Such diseases include, for example, infection, diabetic neur-
opathy, hypertension, sexual dysfunction, cancer, deep vein
thrombosis, tendinopathy, and Duchenne muscular dystro-
phy. In some embodiments, the compositions and medical
devices of the present disclosure may replace or be used in
combination with traditional anti-coagulant drugs and thera-
pies.
In some embodiments, the compositions of the present
disclosure may be formulated into a cream or lotion. Such
creams and lotions may be used to increase circulation in
diabetic and other circulation-deficient patients. The creams
and lotions mayalso be applied to the scalp as a hair growth
treatment. A patient need only apply the cream or lotion and
then expose themselves to a light source or ambient room
lighting to experience a therapeutic effect from photo-re-
leased NO.
EXPERIMENTAL EXAMPLES
The following examples are provided to more fully illus-
trate some of the embodiments disclosed hereinabove. It
should be appreciated by those of ordinary skill in the art that
the techniques disclosed in the examples that follow represent
techniques that constitute illustrative modes for practice of
the disclosure. Those of ordinary skill in the art should, in
light of the present disclosure, appreciate that many changes
can be madein the specific embodiments that are disclosed
and still obtain a like or similar result without departing from
the spirit and scope ofthe disclosure.
Example 1
Synthesis of Titanium Dioxide Nanotubes
P25 titanium dioxide was dissolved in sodium hydroxide
solution to form sodium titanate sheets. The solution contain-
ing sodium titanate sheets was then treated with acid and
annealed to form titanium dioxide nanotubes.
Example 2
Deposition of PbS Quantum Dots on Titantum
Dioxide Nanotubes
FIG. 1 shows an illustrative process through which PbS
quantum dots may be deposited on titanium dioxide nano-
tubes. Titanium dioxide nanotubes 1 were exposedto thiolac-
tic acid in solution, thereby resulting in adsorption ofthiolac-
tic acid on the surface of thiol-tethered titantum dioxide
nanotube 2. Exposure of thiol-tethered titantum dioxide
nanotube 2 to a 0.2 M solution of Pb(NO,), resulted in coor-
dination ofPb**to the free thiol in 2 to produce Pb?*-tethered
titanium dioxide nanotube 3. Exposure of 3 to a 0.5 M solu-
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tion ofNa,Sresultedin the precipitation ofthe Pb** cation as
PbS quantum dots in PbS quantum dottitanium dioxide nano-
tube 4. In PbS quantum dot titanium dioxide nanotube 4,the
structure of the thiolactic acid moiety has been omitted for
clarity.
The embodiment shown in FIG. 1 demonstrates the depo-
sition of the PbS quantum dots on the exterior surface of the
titanium dioxide nanotubes. However, by first blocking the
outer surface of the titantum dioxide nanotubes with a cat-
ionic surfactant (e.g., tetraalkylammonium salts) before fol-
lowing the procedure outlined in FIG. 1, the PbS quantum
dots were instead deposited on the interior surface of the
titantum dioxide nanotubes. FIGS. 2A and 2B show illustra-
tive TEM images of PbS quantum dots deposited on the
interior surface oftitanium dioxide nanotubes.
The titantum dioxide nanotubes containing PbS quantum
dots deposited on the interior surface were thermally stable
upon annealing at 500° C. in Ar atmosphere, except for sin-
tering of the PbS quantum dots into PbS nanorods contained
within the titanium dioxide nanotubes. FIG. 3 showsan illus-
trative TEM image showing PbS nanorodswithin theinterior
of titantum dioxide nanotubes. The length of the PbS nano-
rods was estimated to be about 25 nm. Another significant
outcome of annealing was that the titantum dioxide nano-
tubes were thermally stable and did not collapse or unroll
upon heating, as occurs in the absence of PbS quantum dots.
Therefore, it canbe inferred that the PbS quantum dots depos-
ited on the interior surface of the titanium dioxide nanotubes
conferred additional stability to the titantum dioxide nano-
tubes themselves.
Example 3
Synthesis and NO Release of
Diazeniumdiolate-Modified Titanium Dioxide
Nanotubes
FIG. 4 shows a schematic of an illustrative synthesis of
diazeniumdiolate-modified titanium dioxide nanotubes 12.
Titanium dioxide nanotubes 10 were suspended in xylene
solvent, and an organosilanol linker species was added. The
silanol moieties were hydrolyzed upon treatment, and a cova-
lent bond formedto link the silane to the titanium dioxide
nanotubesthrough a silicon-oxygen covalent bond. Next, the
silane-functionalized titanium dioxide nanotubes 11 were
exposed to 5 atm ofNO gasto form diazentumdiolate-modi-
fied titanium dioxide nanotubes 12. A numberof organosil-
anol linker species similar to that shown in FIG. 4 are com-
mercially available and could be used equivalently to bond to
the titanium dioxide nanotubes.
Nitric oxide release from the diazeniumdiolate-modified
titanium dioxide nanotubes was stimulated by ultraviolet
radiation provided from a 450 W mercury are lamp. FIG. 5
showsillustrative comparative FTIR spectra of diazentumdi-
olate-modified titantum dioxide nanotubes before and after
exposureto ultraviolet radiation. The band centered at 1387
emin spectrum 20 is characteristic ofthe diazeniumdiolate
moiety. This band disappeared in spectrum 21 as a result of
NOrelease. The released NO concentration after 15 hours of
irradiation was up to 0.172 mmol NO per 50 mg ofdiazeni-
umdiolate-modified titanium dioxide nanotubes. The diaz-
entumdiolate-modified titanium dioxide nanotubes of this
example did not contain deposited PbS quantum dots. How-
ever, the quantum dots could be added in a mannersimilar to
that described in Example 2 to lower the band gap from the
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ultraviolet region to the visible or near-infrared region of the
electromagnetic spectrum (see Example 4).
Example 4
Synthesis and NO Release of
S-Nitrosothiol-Modified Titanium Dioxide
Nanotubes
Thiols are believed to be involvedin binding and metabo-
lism ofNO in vivo, and it has been shown that model systems
such as N-acetylcysteine and glutathione bind and releaseNO
photochemically. These and other carboxy]l-containing thiols
can be deposited on the titanium dioxide nanotubes through
their carboxyl group. FIG. 6 shows a schematic of an illus-
trative synthesis of S-nitrosothiol-modified titanium dioxide
nanotubes containing PbS quantum dots. As shownin FIG.6,
titanium dioxide nanotubes 30 were treated with thiolactic
acid, Pb?* and PbS to form PbS quantum dots deposited on
the titanium dioxide nanotubes by following the procedure
outlined in Example 2. PbS quantum dot titanium dioxide
nanotube 31 was then treated with cysteine to form thiol-
modified titantum dioxide nanotube 32 in which the cysteine
is adsorbed to the titanium dioxide nanotube throughits car-
boxyl group. Exposure of thiol-modified titantum dioxide
nanotube 32 to NO gas at 60 psi for 24 hours resulted in
formation of S-nitrosothiol-modified titanium dioxide nano-
tube 33. Alternatively, the thiol could be reacted with sodium
nitrite in HCl solution to form the S-nitrosothiol.
The S-nitrosothiol-modified titanium dioxide nanotubes
33 released NO upon exposure to near infrared electromag-
netic radiation using a Ray-Sorb filter. FIG. 7 showsa plot of
near-infrared photochemical release of NO versus time for
S-nitrosothiol-modified titantum dioxide nanotubes both
before and after purification by filtration. Comparative data
for S-nitrosothiol-modified titanium dioxide nanotubes not
containing PbS quantum dots is also presented for purposes
of comparison. As shown in FIG. 7, curves 40 and 41 indi-
cated that 5-nitrosothiol-modified titantum dioxide nano-
tubes released NO upon exposure to near-infrared electro-
magnetic radiation both before (41) and after (40)
purification. In contrast, 5-nitrosothiol-modified titanium
dioxide nanotubes not containing PbS quantum dots only
appreciably released NO before purification by filtration
(curve 42) but not after purification (curve 43). The difference
in NO release between curves 42 and 43 can beattributed to
physical adsorption ofNO bythetitanium dioxide nanotubes
during S-nitrosothiol formation. This adsorbed NO is weakly
bound and released even in the dark. As shown in FIG. 7,
adsorbed NO was not fully removed from S-nitrosothiol-
modified titantum dioxide nanotubes not containing PbS
quantum dots before purification, as evidenced bythe strong
NOrelease in curve 42. In contrast, strong NO release was
maintainedin S-nitrosothiol-modified titanium dioxide nano-
tubes containing Pbs quantum dots both before and after
purification, as evidenced by strong NOrelease in both curves
40 and 41.
Example 5
Synthesis Metal Complex-Modified Titanium
Dioxide Nanotubes
Titanium dioxide nanotubes were functionalized with an
organosilane linker species following the procedure set forth
in Example3. In the present example, however, the organosi-
lane contained a ligand donor, such as imidazole or pyridine,
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whichis operable for coordinating a metal complex. Follow-
ing organosilane attachment, a metal nitrosyl complex was
coordinatedto the ligand donorattachedto the titanium diox-
ide nanotubes. Ruthenium nitrosyl complexes are among the
best studied metal nitrosyl complexes, and a ruthenium salen
nitrosyl complex was used in the present example.
Example 6
Polymer Wrapping of Titanium Dioxide Nanotubes
Poly-L-arginine was mixed with a solution of functional-
ized titanium dioxide nanotubes. FIGS. 8A and 8B show
illustrative TEM images of titantum dioxide nanotubes
wrapped with poly-L-arginine. FIG. 8A presents a side view
TEM image, and FIG.8B presents a top view TEM image. As
shown in the TEM images, the titanium dioxide nanotubes
were well wrapped by the water-soluble polymer.
Example 7
Imaging Titanium Dioxide Nanotubes In Vivo and In
Vitro
Gold nanoparticles attached to the titantum dioxide nano-
tubes were used to image the titantum dioxide nanotubes in
vivo and in vitro. Such gold nanoparticles are known to emit
in the nearinfrared region of the electromagnetic spectrum,
and such emissionsare transparent to humantissue. A modi-
fication ofExample 2 wasused to attach gold nanoparticles to
the titanium dioxide nanotubes. After depositing thiolactic
acid on the titanium dioxide nanotubes, Au?* was coordinated
to the thiol moiety. Thereafter, a solution ofHAuCL, was used
to produce Au nanoparticles with an averageparticle size of
1.620.2 nm. FIG. 9 showsanillustrative TEM image ofAu
nanoparticles deposited on titanium dioxide nanotubes. FIG.
10 showsanillustrative confocal microscopy image of Au
nanoparticles deposited on titanium dioxide nanotubesafter
wrapping in poly-L-arginine.
From the foregoing description, one ofordinary skill in the
art can easily ascertain the essential characteristics of this
disclosure, and without departing from the spirit and scope
thereof, can make various changes and modifications to adapt
the disclosure to various usages and conditions. The embodi-
ments described hereinabove are meantto beillustrative only
and should not be taken as limiting ofthe scopeofthe disclo-
sure, which is defined in the following claims.
Whatis claimed is the following:
1. A composition for release of nitric oxide under photo-
chemical conditions, comprising annealed titanium dioxide
nanotubes, said titanium dioxide nanotubes having a nitric
oxide-releasing compound deposited on the titantum dioxide
nanotubes with a organosilane linker and a semiconductor
material covalently attached inside of said titanium dioxide
nanotubes, wherein the semiconductor material comprises a
quantum dot material selected from the group consisting of
PbS, PbSe, CuS, Cu,S, FeS,, CdS, CdSe, CdTe, ZnS, Ag,S,
CulnS,, Rh,S, and RuS,andthe nitric oxide-releasing com-
poundis selected from the group consisting of diazeniumdi-
olate, a S-nitrosothiol and a metal nitrosyl complex and
releases nitric oxide upon exposure to photochemicalradia-
tion of 700 nm to 1400 nm.
2. The composition ofclaim 1, wherein the semiconductor
material is PbS.
3. The composition of claim 1, wherein a portion of the
semiconductor material is also deposited on the exterior sur-
face of the titanium dioxide nanotubes.
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4. The composition of claim 1, whereinat least a portion of
the nitric oxide-releasing compoundis deposited on the exte-
rior surface ofthe titanium dioxide nanotubes.
5. The composition of claim 1, further comprising:
a polymer wrapping the titanium dioxide nanotubes.
6. The composition of claim 1, wherein the polymeris a
water-soluble polymer.
7. The composition according to claim 1, said composition
further comprising tissue-targeting moieties deposited on the
exterior surface of the titantum dioxide nanotubes.
8. The composition according to claim 7, wherein said
tissue targeting moieties are antibodies, peptides, DNA or
RNA.
9. The composition according to claim 8, wherein said
tissue targeting moieties are antibodies.
* * * * *
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